COMMUNIQUÉS West-GlobeNewswire

Cognition Therapeutics to Report Fourth Quarter and Full Year 2024 Results
13/03/2025
Conference Call and Live Audio Webcast Scheduled for March 20, 2025 PURCHASE, N.Y., March 13, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical stage company developing product candidates [...]
Generation Bio Reports Business Highlights and Fourth Quarter and Full Year 2024 Financial Results
13/03/2025
- Company is applying its T cell-selective lipid nanoparticle to develop siRNA therapeutics for T cell-driven autoimmune diseases - Lead target and indication to be announced MY 2025 - Cash balance of $185.2 million [...]
Sutro Biopharma Announces Strategic Portfolio Review Resulting in the Prioritization of its Next-Generation ADC Pipeline
13/03/2025
– Sutro will rapidly advance next-generation exatecan and dual-payload ADC programs; luveltamab tazevibulin development to be deprioritized as Sutro continues to seek a partner – – Three INDs for wholly-owned programs [...]
The Joint Corp. Reports Fourth Quarter and Year-end 2024 Financial Results
13/03/2025
- Grew revenue from continuing operations 10% annually and 14% quarterly compared to the same period in 2023 - - Increased system-wide sales 9% for both the year and Q4 2024 – SCOTTSDALE, Ariz., March 13, 2025 (GLOBE [...]
IN8bio Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Highlights
13/03/2025
Ongoing Phase 1 and Phase 2 clinical programs continue to exhibit long-term durable remissions in hard-to-treat cancers, including glioblastoma (GBM) and 100% of treated Acute Myeloid Leukemia (AML) patients remaining [...]
Evoke Pharma, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
13/03/2025
Q4 2024 revenue increased 24.6% over Q3 2024 ; Full-year 2024 revenue grew 97.8% year-over-year Strong growth in key commercial metrics, including prescriber base, fill rates, and patient enrollments Secured $14.3 [...]
Allogene Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Update
13/03/2025
Momentum Builds Across Programs with Key Data Milestones Expected in 2025 Cemacabtagene Ansegedleucel (Cema-Cel): First-Line (1L) Consolidation in Large B-Cell Lymphoma (LBCL) Ongoing Pivotal Phase 2 ALPHA3 Trial [...]
aTyr Pharma Announces Fourth Quarter and Full Year 2024 Results and Provides Corporate Update
13/03/2025
Topline data from Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis expected in the third quarter of 2025. Fourth positive DSMB review for efzofitimod in Phase 3 EFZO-FIT™ study reinforces its favorable [...]
Senti Bio Appoints Feng Hsiung to Board of Directors
13/03/2025
– Company also announced inducement grants under Nasdaq Listing Rule 5635(c)(4) – SOUTH SAN FRANCISCO, Calif., March 13, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio,” or the “Company”), a [...]
Lyra Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
13/03/2025
Company continues to focus on upcoming results from ENLIGHTEN 2 pivotal Phase 3 trial in CRS patients, expected in 2Q 2025 In parallel, the Company continues to analyze data and explore opportunities for LYR-210 in CRS [...]
Nurix Therapeutics Appoints Drug Development Expert Roy D. Baynes, MB.Bch., M.Med., Ph.D., to Its Board of Directors
13/03/2025
Dr. Baynes has been a member of Nurix’s Medical Advisory Board since 2023 SAN FRANCISCO, March 13, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on [...]
Virbac: Public Release of the Year-End Consolidated Accounts at 31 December 2024
13/03/2025
Public release of Virbac Consolidated Accounts at 31 December 2024. The Group released its 2024 Consolidated Accounts. The document is available on the corporate website, at corporate.virbac.com, under “Investors”, “ [...]
Virbac: Communiqué de mise à disposition des comptes consolidés au 31 décembre 2024
13/03/2025
Communiqué de mise à disposition des comptes consolidés au 31 décembre 2024. Le Groupe annonce avoir mis à la disposition du public ses comptes consolidés au 31 décembre 2024 sur le site internet du Groupe, à l’adresse [...]
Annual General Meeting in ALK-Abelló A/S held on 13 March 2025
13/03/2025
ALK ( ALKB:DC / OMX: ALK B / AKBLF ): ALK-Abelló A/S held its Annual General Meeting on 13 March 2025. The Annual General Meeting transacted the following business: Approval of the annual report 2024 and discharge of [...]
EssilorLuxottica: Disclosure of Share Capital and Voting Rights Outstanding as of March 12, 2025
13/03/2025
Disclosure of Share Capital and Voting Rights Outstanding as of March 12, 2025 (Pursuant to Article L.233-8 II of the French Commercial Code and articles 221-1 and 223-16 of the General Regulations of the Autorité des [...]
EssilorLuxottica: Nombre total de droits de vote et d’actions composant le capital social au 12 mars 2025
13/03/2025
Nombre total de droits de vote et d’actions composant le capital social au 12 mars 2025 (Conformément à l’article L.233-8 II du Code de Commerce et aux articles 221-1 et 223-16 du Règlement Général de l’AMF) Paris, [...]
GUERBET : Nombre d'actions et de droits de vote composant le capital de la société au 28 février 2025
13/03/2025
GUERBET : Nombre d'actions et de droits de vote composant le capital de la société au 28 février 2025 En application de l'article L. 233-8 II du code de commerce et de l'article 222-12-5 du règlement général de l'AMF, [...]
Virbac: 2024 Annual results
13/03/2025
Very strong revenues increase of 13.6% at constant exchange rates, driven by: dynamic organic growth (+7.5%) strategic contribution of our acquisitions (+6.1%) 2024 operating income 2 at an all-time high of 16.6% of [...]
VIRBAC: Résultats 2024
13/03/2025
Chiffre d’affaires en très forte progression de 13,6% à taux de change constant tirée par : une croissance organique dynamique (+7,5%) l’apport stratégique de nos acquisitions (+6,1%) Un résultat opérationnel 2 2024 à [...]

Pages